株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6) :パイプライン製品の分析

Histone Deacetylase 6 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 363572
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6) :パイプライン製品の分析 Histone Deacetylase 6 - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 141 Pages
概要

当レポートでは、ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6) を標的とした治療薬の開発に関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6) の概要

治療薬の開発

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):開発中の製品 - 開発段階別

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):開発中の製品 - 治療範囲別

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):開発中の製品 - 適応症別

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):企業で開発中の製品

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):大学/機関で開発中の製品

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6) の治療薬開発に従事している企業

  • Acetylon Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • HitGen LTD
  • Kancera AB
  • Karus Therapeutics Limited
  • Lycera Corp.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • OncoHoldings, Inc.
  • Quimatryx, S.L.
  • Sigma-Tau S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • 武田薬品工業
  • TetraLogic Pharmaceuticals

薬剤プロファイル

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):休止中のプロジェクト

ヒストン脱アセチル化酵素6 (ヒストンデアセチラーゼ6 - HDAC6):主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by ATP Biopharm, H2 2019
  • Pipeline by Augustine Therapeutics, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by Curis Inc, H2 2019
  • Pipeline by Eikonizo Therapeutics Inc, H2 2019
  • Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Hillstream BioPharma Inc, H2 2019
  • Pipeline by HitGen LTD, H2 2019
  • Pipeline by Jubilant Biosys Ltd, H2 2019
  • Pipeline by Kancera AB, H2 2019
  • Pipeline by Karus Therapeutics Ltd, H2 2019
  • Pipeline by Konruns Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Medivir AB, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by OnKure Inc, H2 2019
  • Pipeline by Quimatryx SL, H2 2019
  • Pipeline by Selenity Therapeutics Inc, H2 2019
  • Pipeline by Shuttle Pharmaceuticals Inc, H2 2019
  • Pipeline by SignalRx Pharmaceuticals Inc, H2 2019
  • Pipeline by SK Biopharmaceuticals Co Ltd, H2 2019
  • Pipeline by Starwise Therapeutics LLC, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Dormant Products, H2 2019 (Contd..3), H2 2019
  • Dormant Products, H2 2019 (Contd..4), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2047TDB

Summary

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 49 molecules. Out of which approximately 40 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 6 - Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 22 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Gastrointestinal, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Alzheimer's Disease, Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type II, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Breast Cancer, Burkitt Lymphoma, Cervical Cancer, CNS Lymphoma, Colon Cancer, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Gallbladder Cancer, Gastric Cancer, Gliosarcoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycystic Kidney Disease, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Tauopathies, Ulcerative Colitis and Unspecified.

Furthermore, this report also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
  • ATP Biopharm
  • Augustine Therapeutics
  • Bristol-Myers Squibb Co
  • Chong Kun Dang Pharmaceutical Corp
  • CStone Pharmaceuticals Co Ltd
  • Curis Inc
  • Eikonizo Therapeutics Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hillstream BioPharma Inc
  • HitGen LTD
  • Jubilant Biosys Ltd
  • Kancera AB
  • Karus Therapeutics Ltd
  • Konruns Pharmaceutical Co Ltd
  • Medivir AB
  • Merck & Co Inc
  • OnKure Inc
  • Quimatryx SL
  • Selenity Therapeutics Inc
  • Shuttle Pharmaceuticals Inc
  • SignalRx Pharmaceuticals Inc
  • SK Biopharmaceuticals Co Ltd
  • Starwise Therapeutics LLC
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
  • ACY-1083 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACY-738 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACY-775 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADV-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer